Clinical Trials Logo

Clinical Trial Summary

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00512876
Study type Interventional
Source Walter Reed Army Medical Center
Contact
Status Completed
Phase N/A
Start date August 2007
Completion date January 2011

See also
  Status Clinical Trial Phase
Completed NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Phase 2/Phase 3
Completed NCT00004430 - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization N/A
Completed NCT00769145 - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Phase 1
Completed NCT01257750 - Treatment of Corneal Neovascularization With Topical Pazopanib Phase 1/Phase 2
Recruiting NCT04787471 - Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/Phase 3
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting NCT00992849 - Bevacizumab for the Treatment of Corneal Neovascularization Phase 2
Withdrawn NCT00515684 - Corneal Thinning During Topical Bevacizumab Therapy N/A
Terminated NCT02797704 - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Phase 1/Phase 2
Terminated NCT01868360 - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Phase 1
Withdrawn NCT02042027 - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Phase 1
Recruiting NCT04215393 - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Phase 1
Completed NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization Phase 4
Recruiting NCT05659940 - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed NCT00559936 - Topical Avastin for Treatment of Corneal Neovascularization Phase 1
Completed NCT01072357 - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Recruiting NCT04620109 - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment Phase 1
Recruiting NCT05011916 - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization Phase 1/Phase 2
Completed NCT01996826 - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Terminated NCT00915590 - Topical IL-1-Ra for Treatment of Corneal Neovascularization Phase 1/Phase 2